PATHOGENESIS OF HYPERLIPIDEMIA IN THE NEPHROTIC SYNDROME

被引:21
作者
ATTMAN, PO [1 ]
ALAUPOVIC, P [1 ]
机构
[1] OKLAHOMA MED RES FDN, LIPOPROT & ATHEROSCLEROSIS RES PROGRAM, OKLAHOMA CITY, OK 73104 USA
关键词
Apolipoproteins; Hyperlipidemia; Lipids; Nephrotic syndrome;
D O I
10.1159/000168197
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Both increased synthesis and decreased clearance of lipoproteins may contribute to the hyperlipoproteinemia which frequently complicates the nephrotic syndrome with increased levels of total and low-density lipoprotein (LDL) cholesterol as the most characteristic abnormality. The hyperlipoproteinemia may also be characterized by elevated levels of triglycerides, increased concentrations of Apo B, Apo C and Apo E and reduced levels of Apo A-I and Apo A-II. The increased lipoprotein synthesis occurs in partly undefined mechanisms related to proteinuria, hypoalbuminemia and, possibly, increased availability of mevalonate as a substrate for cholesterol synthesis. Urinary loss of high-density lipoprotein (HDL) components and other liporegulatory factors may contribute to decreased activity of lipolytic enzymes and result in impaired clearance of cholesterol- and triglyceride-rich lipoproteins of lower densities and altered composition of HDL. The variability in these two metabolic abnormalities may account for the corresponding variability in lipoprotein profiles of patients with the nephrotic syndrome. © 1990 S. Karger AG, Basel.
引用
收藏
页码:69 / 75
页数:7
相关论文
共 49 条
[41]  
SHORT CD, 1986, KIDNEY INT, V29, P1224, DOI 10.1038/ki.1986.131
[42]  
SOKOLOVSKAYA IV, 1984, NEPHRON, V37, P49, DOI 10.1159/000183207
[43]   CHARACTERIZATION OF GLYCOSAMINOGLYCANS IN URINE FROM PATIENTS WITH NEPHROTIC SYNDROME AND CONTROL SUBJECTS, AND THEIR EFFECTS ON LIPOPROTEIN-LIPASE [J].
STAPRANS, I ;
GARON, SJ ;
HOPPER, J ;
FELTS, JM .
BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 678 (03) :414-422
[44]   GLYCOSAMINOGLYCANS AND CHYLOMICRON METABOLISM IN CONTROL AND NEPHROTIC RATS [J].
STAPRANS, I ;
FELTS, JM ;
COUSER, WG .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1987, 36 (05) :496-501
[45]   LOVASTATIN THERAPY IN NEPHROTIC HYPERLIPIDEMIA - EFFECTS ON LIPOPROTEIN METABOLISM [J].
VEGA, GL ;
GRUNDY, SM .
KIDNEY INTERNATIONAL, 1988, 33 (06) :1160-1168
[46]   INHIBITION OF LIPOPROTEIN-LIPASE BY PLASMA FROM CHILDREN WITH THE STEROID RESPONSIVE NEPHROTIC SYNDROME [J].
VERMYLEN, C ;
LEVIN, M ;
BARRATT, TM ;
MULLER, DPR .
PEDIATRIC RESEARCH, 1987, 22 (02) :197-200
[47]   CARDIOVASCULAR-DISEASE AND THE NEPHROTIC SYNDROME - THE OTHER SIDE OF THE COIN [J].
WASS, V ;
CAMERON, JS .
NEPHRON, 1981, 27 (02) :58-61
[48]   HYPERLIPIDEMIA IN NEPHROTIC SYNDROME [J].
WHEELER, DC ;
VARGHESE, Z ;
MOORHEAD, JF .
AMERICAN JOURNAL OF NEPHROLOGY, 1989, 9 :78-84
[49]   REGULATION OF PLASMA-LIPID LEVELS BY PLASMA VISCOSITY IN NEPHROTIC RATS [J].
YEDGAR, S ;
EILAM, O ;
SHAFRIR, E .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 248 (01) :E10-E14